These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35028628)
1. Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent Stone W; Mahamar A; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Youssouf A; Diallo M; Soumare HM; Kaur H; Lanke K; Ter Heine R; Bradley J; Issiaka D; Diawara H; Traore SF; Bousema T; Drakeley C; Dicko A Lancet Microbe; 2022 Jan; 3(1):e41-e51. PubMed ID: 35028628 [TBL] [Abstract][Full Text] [Related]
2. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095 [TBL] [Abstract][Full Text] [Related]
3. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Poespoprodjo JR; Burdam FH; Candrawati F; Ley B; Meagher N; Kenangalem E; Indrawanti R; Trianty L; Thriemer K; Price DJ; Simpson JA; Price RN Lancet Infect Dis; 2022 Mar; 22(3):367-376. PubMed ID: 34710363 [TBL] [Abstract][Full Text] [Related]
4. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE; Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490 [TBL] [Abstract][Full Text] [Related]
6. Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial. Madanitsa M; Barsosio HC; Minja DTR; Mtove G; Kavishe RA; Dodd J; Saidi Q; Onyango ED; Otieno K; Wang D; Ashorn U; Hill J; Mukerebe C; Gesase S; Msemo OA; Mwapasa V; Phiri KS; Maleta K; Klein N; Magnussen P; Lusingu JPA; Kariuki S; Mosha JF; Alifrangis M; Hansson H; Schmiegelow C; Gutman JR; Chico RM; Ter Kuile FO Lancet; 2023 Mar; 401(10381):1020-1036. PubMed ID: 36913959 [TBL] [Abstract][Full Text] [Related]
7. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008 [TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
10. Tamoxifen for adults with hepatocellular carcinoma. Naing C; Ni H; Aung HH Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881 [TBL] [Abstract][Full Text] [Related]
12. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT. Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608 [TBL] [Abstract][Full Text] [Related]
14. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
15. Treatments for intractable constipation in childhood. Gordon M; Grafton-Clarke C; Rajindrajith S; Benninga MA; Sinopoulou V; Akobeng AK Cochrane Database Syst Rev; 2024 Jun; 6(6):CD014580. PubMed ID: 38895907 [TBL] [Abstract][Full Text] [Related]
16. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
17. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661 [TBL] [Abstract][Full Text] [Related]
18. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation. Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138 [TBL] [Abstract][Full Text] [Related]
19. Infliximab for maintenance of medically-induced remission in Crohn's disease. Gordon M; Sinopoulou V; Akobeng AK; Sarian A; Moran GW Cochrane Database Syst Rev; 2024 Feb; 2(2):CD012609. PubMed ID: 38372447 [TBL] [Abstract][Full Text] [Related]
20. Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis. Curry N; Davenport R; Thomas H; Fox E; Lucas J; Evans A; Massou E; Sharma R; Shanmugaranjan S; Rourke C; Newton A; Deary A; Dallas N; Fitzpatrick-Creamer C; Podbielski JM; Wade CE; Edwards A; Benger J; Morris S; Cotton BA; Piercy J; Green L; Brohi K; Stanworth S Health Technol Assess; 2024 Nov; 28(76):1-69. PubMed ID: 39545850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]